Streetbeat News

Earnings

SES

SES shares have experienced an increase following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:58 pm

SIBN

SI-BONE's stock price declined following the announcement of mixed financial results for the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:57 pm

WDAY

Workday, Inc. (NASDAQ:WDAY) reported Q4 earnings of $1.57 per share, beating estimates by 6.8%, with sales of $1.92 billion, a 16.77% increase year-over-year. The company announced the acquisition of HiredScore, reiterated its FY2025 subscription revenue guidance of $7.725 to $7.775 billion, and expects a non-GAAP operating margin of approximately 24.5%. Following the report, analysts adjusted their price targets on WDAY, with changes ranging from a decrease to an increase, reflecting a mixed outlook.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 5:57 pm

EYE

National Vision's shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided positive guidance for the future.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:54 pm

PTLO

Portillo's shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:53 pm

LFWD

ReWalk Robotics Ltd. (NASDAQ:LFWD), also known as Lifeward, reported Q4 earnings with an EPS of $(0.05), missing the consensus of $(0.10). Revenue was $6.9 million, below the $7.22 million estimate. The adjusted gross margin decreased to 47% from 52.8% a year ago, with total operating expenses rising to $8.6 million from $5.7 million. For FY24, Lifeward expects revenue between $28 million and $32 million, with a non-GAAP gross margin in the high 40%s. LFWD shares dropped 3.89% to $0.8911.

Portfolio Pulse from Nabaparna Bhattacharya

February 27, 2024 | 5:53 pm

ERIE

Erie Indemnity's stock price increased following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:48 pm

VERV

Verve Therapeutics shares surged following the announcement of their Q4 financial results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 5:46 pm

JANX

Janux Therapeutics Inc (NASDAQ:JANX) released promising data for its cancer treatments, JANX007 and JANX008, showing significant efficacy and safety. JANX007, targeting metastatic castration-resistant prostate cancer, demonstrated high rates of PSA declines and favorable safety profiles in a Phase 1a trial. JANX008, aimed at various solid tumors, also showed encouraging clinical activity and safety. Following these updates, Janux's stock surged 186.5% to $43.26, yet William Blair considers it undervalued, highlighting the potential of Janux's TRACTr platform.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 5:41 pm

MSFT

SNOW

Snowflake Inc (SNOW) is set to report its Q4 earnings with expectations of 18 cents EPS and $759.10 million in revenues. Analyst Mike Cikos of Needham has a Buy rating on SNOW, with a price target raised to $265, citing an 'outsized benefit' from AI growth and cloud migrations. Snowflake's cloud-native data platform is disrupting the market, with a 21% exposure to Azure, indicating a strategic advantage. The company's focus on unstructured data and the Applica acquisition further positions it against competitors like Databricks.

Portfolio Pulse from Surbhi Jain

February 27, 2024 | 5:40 pm